Senior Manager, Commercial Applications

Overview

The Senior Manager, Commercial Applications is responsible for providing expertise around the implementation and maintenance of Applications for the Commercial Organization in the US for our solid tumor and hematology franchises, as well as any future indications/ drugs. The individual will lead all aspects related to system process integration and on-going support services including hands-on project/vendor management and oversight of technical support in the deployments. This role will report to the AVP, Commercial Excellence.

Responsibilities

• Assess needs and proactively drive analytics and technology solutions on behalf of commercial, ensuring alignment with internal and external partners.
• Provide Veeva training to field users.
• Provide Veeva administrator support to various Veeva applications/modules.
• Understanding or experience working in an agile development lifecycle including development, testing, deployment, and monitoring.
• Own the periodic (weekly, quarterly, etc) processes such as alignments, targeting, call plan, salesforce sizing changes, Survey, Veeva Suggestions, reporting and any/all Quality Assurance associated with those.
• Provide subject matter expertise and be able to develop and configure for the Veeva applications (CRM, Vault Promomats and Medcomm, Link) and the Salesforce.com platform throughout the entire development lifecycle to provide the best solution.
• Develop and Manage processes integrating with other systems such as Veeva Link, Promomats/Medcomms, CDW, MDM, Concur, OneKey, Speaker Programs, etc.
• Lead integration of Digital automation initiatives including Omni-Channel Marketing efforts with CRM systems.
• Besides various Sales and Marketing teams, work collaboratively with cross-functional teams like Medical Affairs, PRC Admin, Market Access (Payer, FRDs, NADs) to provide a complete solution.
• Develop, maintain, and support the Salesforce or Veeva applications as well as all associated documentation.
• Motivated self-starter with excellent communication skills who can lead customers throughout the entire implementation phase.

Qualifications

• BA/BS in a relevant field is required; a Master’s degree is a plus.
• 5-7 years of experience in a Commercial role (Sales, Marketing, Commercial Operations, Commercial IT) within pharma or biotech
• Experience must include Veeva platform, Veeva applications and its modules like Veeva CRM, Veeva Vault, PromoMats, MedComms, Veeva Network, Approved emails and CLM.
• Familiarity with Life Sciences Commercial Business Processes, such as, Customer Engagement, Alignment, Deployment, Targeting, Segmentation, Incentive Comp, Marketing Operations
• Work Location: Bridgewater, NJ (Hybrid-on site 3 days per week).

Please note: this position is classified as a corporate office position. Per the New York employer convenience rule, Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotely.

Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.

Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.

Base Salary Range of $145,000-$175,000. Menarini Stemline offers generous compensation and benefits packages, including Short Term Incentive Programs, Fidelity 401(k) (with company match), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.

The Company

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of hematological and solid tumors. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved

treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123 indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialize Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

Menarini entered into a global license agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.